A Phase 4 interventional study of dabrafenib plus trametinib with or without PD-1 antibody and entrectinib or larotrectinib with or without anti-PD-1 antibdoy in Advanced Thyroid Cancer Patients Who Received Target Therapy, sponsored by Fudan University. Recruiting at 8 sites in China. Per ClinicalTrials.gov, last updated 2025-08-14.
Sponsored by Fudan University · Phase 4, Interventional, and Treatment
How we know · 3 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Thyroid Neoplasms by Fudan University — 11 open to participants now, 11 under way, 2 of them phase 3. Thyroid Neoplasms · Fudan University.
Among the 17 studies in Thyroid Neoplasms by Fudan University, this one has the largest planned enrollment of the 14 interventional ones that give a count, is one of 4 that started in 2020, is the only one in phase 4, reaches primary completion later than 1 of the 10 other live ones, and was the 8th registered.
785 studies on the registry are indexed under Thyroid Neoplasms; 203 are open to participants now.
Browse Thyroid Neoplasms studies →11 of the 17 studies in Thyroid Neoplasms by Fudan University are open now, in 1 country. Recruiting first, the newest first:
Fudan University · Sites in China
Ages 18+
Fudan University · Sites in China
Ages 18+
Fudan University · Sites in China
Ages 18+
Fudan University · Sites in China
Ages 14–80
Fudan University · Sites in China
Ages 14–80
By country, each count listing its studies:
Of the 151 Thyroid Neoplasms studies recruiting now, 95 (63%) set no upper age limit and 27 (18%) stop at 75 or younger; 36 take children under 18; 13 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 4 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 800 is above the median of 54 across 520 interventional studies indexed under Thyroid Neoplasms.
Median enrollment 66 across the 14 interventional studies, 48 across the 3 observational. Of the 1 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Fudan University is the lead sponsor of 1,319 studies on the registry; 647 are open to participants now.
3 of the studies in Thyroid Neoplasms by Fudan University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06970353Fudan UniversityPhase II Trial of Tunlametinib in NRAS-Mutant Advanced Thyroid Cancer | 2026-12-30 |
| NCT06195228Fudan UniversityA Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer | 2026-12-31 |
| NCT06530316Fudan UniversityRET Inhibitor for Neoadjuvant Therapy in Locally Advanced RET-altered Thyroid Cancer | 2026-12-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 17 studies in Thyroid Neoplasms by Fudan University, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a retrospective and prospective real-world clinical study of molecular typing in the treatment of advanced thyroid cancer.
The retrospective study : Patients with advanced thyroid cancer who received precise treatment in the 24 participated hospitals from January 2020 to December 2023 were retrieved. The number of previous treatment lines was not limited. Patients who met the inclusion criteria were screened according to the inclusion and exclusion criteria. Demographic information, clinical characteristics, tumor treatment history, medication regimen, adverse reactions, molecular test results, survival follow-up results and other data were collected.
The prospective study : Patients with advanced thyroid cancer who received precise treatment in the 24 Chinese hospitals from January 2024 to April 2027 were enrolled.
see:Arms and Interventions
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
diagnosed locally advanced or recurrent / thyroid cancer that cannot undergo radical surgery meets one of the following requirements:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
advanced or metastatic thyroid cancer patients who are refractory to radioiodine treatment
Drug: dabrafenib plus trametinib with or without PD-1 antibody · Drug: entrectinib or larotrectinib with or without anti-PD-1 antibdoy · Drug: pralsetinib or selpercatinib with or without anti-PD-1 antibdoy · Drug: anlotinib or anlotinib plus anti-PD-1 antibody · Drug: lenvatinib plus anti-PD-1 antibody · Drug: Other Targets: precise treatment based on the target
advanced or metastatic differentiated thyroid cancer patients who are not suitable for radio iodine therapy, for example, DTC patients with huge neck tumor but cannot receive the thyroid ectomy
Drug: dabrafenib plus trametinib with or without PD-1 antibody · Drug: entrectinib or larotrectinib with or without anti-PD-1 antibdoy · Drug: pralsetinib or selpercatinib with or without anti-PD-1 antibdoy · Drug: anlotinib or anlotinib plus anti-PD-1 antibody · Drug: lenvatinib plus anti-PD-1 antibody · Drug: Other Targets: precise treatment based on the target
patients with advanced or metastatic medullary thyroid cancer
Drug: dabrafenib plus trametinib with or without PD-1 antibody · Drug: entrectinib or larotrectinib with or without anti-PD-1 antibdoy · Drug: pralsetinib or selpercatinib with or without anti-PD-1 antibdoy · Drug: anlotinib or anlotinib plus anti-PD-1 antibody · Drug: lenvatinib plus anti-PD-1 antibody · Drug: Other Targets: precise treatment based on the target
patients with advanced or metastatic High-grade or poorly differentiated thyroid cancer
Drug: dabrafenib plus trametinib with or without PD-1 antibody · Drug: entrectinib or larotrectinib with or without anti-PD-1 antibdoy · Drug: pralsetinib or selpercatinib with or without anti-PD-1 antibdoy · Drug: anlotinib or anlotinib plus anti-PD-1 antibody · Drug: lenvatinib plus anti-PD-1 antibody · Drug: Other Targets: precise treatment based on the target
patients with anaplastic thyroid cancer
Drug: dabrafenib plus trametinib with or without PD-1 antibody · Drug: entrectinib or larotrectinib with or without anti-PD-1 antibdoy · Drug: pralsetinib or selpercatinib with or without anti-PD-1 antibdoy · Drug: anlotinib or anlotinib plus anti-PD-1 antibody · Drug: lenvatinib plus anti-PD-1 antibody · Drug: Other Targets: precise treatment based on the target
advanced thyroid cancer patients who harbor BRAF V600E mutation
advanced thyroid cancer patients who harbor NTRK mutation
advanced thyroid cancer patients who harbor RET fusion or medullary thyroid carcinoma patients who habor RET mutation.
For patients with medullary carcinoma, if there is no RET gene mutation or RET gene mutation is unknown
Advanced thyroid cancer patients who don't harbor the above gene mutation or could not afford the cost of precision treatment even with the above gene mutation
Advanced thyroid cancer patients who had other treatment targets not included above
This study also gives LenvatinibStudies of LenvatinibLenvatinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., EntrectinibStudies of EntrectinibEntrectinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.
Objective Response Rate(ORR)
Complete remission rate+ partial remission rate
Time frame: up to approximately 3 years
Duration of Response(DOR)
Time from the date of first partial remission or complete remission to the date of disease progression, or death of any cause, or date of lost follow-up, whichever comes first, otherwise subject data were censored at time last known disease free.
Time frame: up to approximately 3 years
Disease Control Rate(DCR)
Complete remission rate+ partial remission rate+stable disease rate
Time frame: up to approximately 3 years
Time to response(TTR)
Time from the initiation of the treatment to the first remission
Time frame: up to approximately 3 years
Progression Free Survival(PFS)
Time from the date of enrollment to of disease progression, or death of any cause, or date of lost follow-up, whichever comes first, otherwise subject data were censored at time last known disease free.
Time frame: up to approximately 3 years
Overall survival(OS)
Time from the date of enrollment to data of death from any cause, or date of lost follow-up, whichever comes first, and otherwise censored at time last known alive.
Time frame: up to approximately 3 years
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2020 (actual). Primary completion is estimated for Dec 2026, 83 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Lenvatinib · Entrectinib